CRNX vs HRMY
CRNX: Crinetics Pharmaceuticals is a clinical-stage biotechnology company developing small molecule precision medicines for rare endocrine diseases and related tumors. HRMY: Harmony Biosciences is a neuroscience-focused biopharmaceutical company commercializing WAKIX (pitolisant), the first-in-class non-controlled H3 receptor antagonist for narcolepsy, with an expanding pipeline in rare epilepsy and sleep disorders.
Side-by-side fundamentals
| Metric | CRNX | HRMY | Edge |
|---|---|---|---|
| Price as of 2026-08-04 close | $83.86 | $38.78 | |
| Market cap as of 2026-08-05 | $8.8B | $2.2B | |
| P/E as of 2026-08-05 | n/a | 15.27 | |
| PEG as of 2026-08-05 | -0.73 | n/a | |
| Net margin as of 2026-08-05 | -2747.2% | +16.2% | HRMY higher |
| Gross margin as of 2026-08-05 | +86.0% | +76.5% | CRNX higher |
| Operating margin as of 2026-08-05 | -3020.3% | +21.1% | HRMY higher |
| ROE as of 2026-08-05 | -44.0% | +17.2% | HRMY higher |
| ROA as of 2026-08-05 | -39.6% | +12.0% | HRMY higher |
| Debt / equity as of 2026-08-05 | 0.00 | 0.17 | CRNX lower |
| Revenue growth (YoY) as of 2026-08-05 | +2277.5% | +20.7% | CRNX higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +25.6% | |
| Beta as of 2026-08-05 | 0.02 | 1.00 | |
| 1-year return as of 2026-08-04 close | +197.2% | +9.1% | CRNX higher |
Fundamentals: market data, as of 2026-08-05. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-04.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.